Bavarian Nordic develops, manufactures, and commercializes life-saving vaccines. They offer smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola vaccines under various names. The company is also developing treatments for smallpox, RSV, and SARS-CoV-2. They have partnerships with AdaptVac, National Cancer Institute, and Public Health Service. Operations are in multiple countries across Europe, North America, Asia, Australia, and South America. The company was founded in 1992 and is headquartered in Denmark.
| Indicator | Value |
|---|---|
| PER | 15.0 |
| EV/EBITDA | 7.9 |
| Price/Free Cash Flow' | 56.3 |
| ROIC | 17.1% |
| Net Debt/EBITDA | 100.0 |